pyrazines has been researched along with Hematologic Neoplasms in 59 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.69) | 18.2507 |
| 2000's | 31 (52.54) | 29.6817 |
| 2010's | 23 (38.98) | 24.3611 |
| 2020's | 4 (6.78) | 2.80 |
| Authors | Studies |
|---|---|
| Abbasov, H; Abishov, E; Aksu, T; Akyay, A; Albayrak, C; Andıç, N; Ar, MC; Ataş, Ü; Aydın Kaynar, L; Balık Aydın, B; Baş, V; Baydar, M; Beköz, HS; Beksaç, M; Bolaman, AZ; Can, F; Çelik, S; Çeneli, Ö; Cengiz Seval, G; Çiftçiler, R; Civriz Bozdağ, S; Demir, AM; Demirci, U; Demircioğlu, S; Diz Küçükkaya, R; Doğan, A; Eroğlu Küçükdiler, H; Erol, V; Göksoy, HS; Güler, N; Gündüz, E; Gürman, G; Gürsoy, V; Güven, ZT; Hindilerden, F; İlhan, O; İnce, İ; Kaynar, L; Keklik, M; Kurt Yüksel, M; Maral, S; Mutlu, YG; Özcan, M; Özkalemkaş, F; Özkocaman, V; Özkurt, ZN; Özsan, GH; Sadri, S; Selim, C; Sevindik, ÖG; Terzi, H; Topçuoğlu, P; Toprak, SK; Ünal, Ş; Üsküdar Teke, H; Yağcı, M; Yavaşoğlu, İ; Yavuz, B; Yavuz, Y; Yegin, ZA; Yılmaz, U; Yönal Hindilerden, İ; Yücel, OK | 1 |
| Mungmunpuntipantip, R; Wiwanitkit, V | 1 |
| Fancher, KM; Pappacena, JJ | 1 |
| Danilov, AV; Persky, DO | 1 |
| Adamia, S; Buhrlage, SJ; Case, AE; Dubreuil, P; Gokhale, PC; Gray, N; Griffin, JD; Letard, S; Liu, X; Meng, C; Sattler, M; Stone, RM; Tiv, HL; Wang, J; Weisberg, E; Yang, J | 1 |
| Horton, T; Hunger, SP | 1 |
| Bies, RR; Broxmeyer, HE; Chitnis, SD; Farag, SS; Messina-Graham, S; Strother, RM; Vélez de Mendizábal, N | 1 |
| Anderl, J; Assaraf, YG; Blank, JL; Cloos, J; Jansen, G; Kaspers, GJ; Kirk, CJ; Niewerth, D; van de Ven, PM; van Meerloo, J; Zweegman, S | 1 |
| Agnelli, L; Anderson, KC; Antonini, E; Bertilaccio, MT; Blandino, G; Caligaris-Cappio, F; Carrasco, R; Cottini, F; Dori, M; Hideshima, T; Kimmelman, AC; Kuehl, WM; Marcatti, M; Neri, A; Ponzoni, M; Richardson, PG; Sattler, M; ten Hacken, E; Tonon, G; Wong, KK; Xu, C | 1 |
| Abedi, M; Ames, E; Blazar, BR; Chen, M; Grossenbacher, SK; Jagdeo, J; Mirsoian, A; Murphy, WJ; Pai, CC; Sun, K; Tellez, J | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Mitsiades, CS | 1 |
| Assaraf, YG; Cloos, J; Jansen, G; Kaspers, GJ; Niewerth, D; Zweegman, S | 1 |
| Liu, D; Wu, J; Zhang, M | 1 |
| Crawford, LJ; Irvine, AE; Walker, B | 1 |
| Kolesar, J; Utecht, KN | 1 |
| Almasan, A; Gama, V; Matsuyama, S; Mazumder, S; Plesca, D | 1 |
| Aleskog, A; Carlson, K; Larsson, R; Lindhagen, E; Nygren, P; Wiberg, K | 1 |
| Armitage, JO | 1 |
| Alyea, EP; Antin, JH; Armand, P; Cutler, C; Garcia, M; Ho, VT; Kim, HT; Koreth, J; Ritz, J; Soiffer, RJ; Stevenson, KE | 1 |
| Czuczman, MS; Reddy, N | 1 |
| Guo, H; Mao, J; Sun, C; Wang, J; Zhou, X | 1 |
| Annunziata, CM; Burris, J; Driscoll, JJ | 1 |
| Correia, C; Dai, H; Kaufmann, SH; Lee, SH; Schmitz, I; Smith, AJ; Takahashi, R | 1 |
| Khan, ML; Stewart, AK | 1 |
| Grant, S; Holkova, B | 1 |
| Beebe, DJ; Callander, NS; Kahl, BS; Miyamoto, S; Pak, C; Yang, DT; Young, EW | 1 |
| Esseltine, DL; Mulligan, G | 1 |
| Giralt, S | 1 |
| Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Cutler, C; Ho, VT; Kim, HT; Koreth, J; McDonough, SM; Ritz, J; Soiffer, RJ; Stevenson, KE | 1 |
| Bashir, Q; Bayraktar, UD; Champlin, RE; Ciurea, SO; Qazilbash, M | 1 |
| Belitsky, G; Budunova, I; Gordon, LI; Kirsanov, K; Lesovaya, E; Popa, A; Rosen, ST; Yakubovskaya, M; Yemelyanov, A | 1 |
| Abonour, R; Broxmeyer, HE; Cornetta, K; Farag, SS; Jones, DR; Messina-Graham, S; Robertson, MJ; Schwartz, J; Secrest, A; Srivastava, S; Strother, RM; Wood, L | 1 |
| Cheson, BD | 1 |
| Adams, J; Anderson, JK; Baldwin, AS; Bhagat, R; Depcik-Smith, ND; Elliott, PJ; Esseltine, DL; Guerciolini, R; Lehman, MJ; Mitchell, BS; Novick, SC; O'Connor, OA; Orlowski, RZ; Pien, CS; Shea, TC; Soignet, SL; Stahl, S; Stinchcombe, TE | 1 |
| Richardson, P | 1 |
| Schoenfeldt, M; Wright, JJ; Zerivitz, K | 1 |
| Anderson, KC; Hideshima, T; Richardson, PG | 1 |
| Reddy, GK | 1 |
| Gilles, F; Goy, A | 1 |
| Anderson, K; Hideshima, T; Mitsiades, C; Richardson, PG | 1 |
| Adams, J; Allred, T; Collins, JM; Dees, EC; Esseltine, DL; Gabriel, DA; Garcia, RA; Green, M; Hall, MD; Ivanova, A; Johri, AR; Jones, PE; Kudrik, FJ; Lehman, MJ; Lindley, CM; Mitchell, BS; Natoli, S; Orlowski, RZ; Shea, TC; Trehu, EG; Van Deventer, HW; Voorhees, PM | 1 |
| Anderson, KC; Hideshima, T; Mitsiades, CS; Mitsiades, N; Richardson, PG | 2 |
| Facon, T; Giaccone, G; Khayat, D; Ludwig, H | 1 |
| Einsele, H; Jackson, G; Miguel, JS; Moreau, P | 1 |
| Bay, JO; Blay, JY; Rixe, O; Spano, JP | 1 |
| Orlowski, RZ; Zeger, EL | 1 |
| Ferreri, AJ | 1 |
| Bohlius, J; Engert, A; Hülsewede, H; Kober, T | 1 |
| Amadori, S; Boccadoro, M; Caravita, T; de Fabritiis, P; Palumbo, A | 1 |
| Beck, A; Berkers, CR; Burg, D; Driessen, C; Gogel, J; Kammer, W; Kraus, M; Ovaa, H; Overkleeft, H; Reich, M; Rückrich, T | 1 |
| Walker, K | 1 |
| Armand, JP; Burnett, AK; Drach, J; Harousseau, JL; Löwenberg, B; San Miguel, J | 1 |
| Hahne, JC; Heider, U; Lamottke, B; Rademacher, J; Sezer, O; Sterz, J; Terpos, E; von Metzler, I | 1 |
| Kensler, TW; Roebuck, BD; Rogers, AE | 1 |
| Cheson, BD; Gore-Langton, RE; Hillsamer, VL; Wright, J | 1 |
| Adams, J | 2 |
27 review(s) available for pyrazines and Hematologic Neoplasms
| Article | Year |
|---|---|
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Clinical Trials as Topic; Disease Progression; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Middle Aged; Piperidines; Practice Patterns, Physicians'; Pyrazines; Safety; Treatment Outcome; United States; United States Food and Drug Administration | 2021 |
Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Proteasome Inhibitors; Pyrazines | 2015 |
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Proteasome inhibitors: a therapeutic strategy for haematological malignancy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Nucleus; Cytoplasm; Hematologic Neoplasms; Humans; Leukemia; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2008 |
Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Hematologic Neoplasms; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Pyrazines | 2008 |
Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Pyrazines | 2010 |
Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematologic Neoplasms; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation | 2012 |
Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies.
Topics: Boronic Acids; Bortezomib; Cyclin-Dependent Kinases; Enzyme Inhibitors; Flavonoids; Hematologic Neoplasms; Humans; NF-kappa B; Piperidines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2011 |
An historic perspective of proteasome inhibition.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Screening Assays, Antitumor; Hematologic Neoplasms; History, 20th Century; History, 21st Century; Humans; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Structure-Activity Relationship; Ubiquitin | 2012 |
Fifty years of melphalan use in hematopoietic stem cell transplantation.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2013 |
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
Clinical update: proteasome inhibitors in hematologic malignancies.
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Down-Regulation; Drug Administration Schedule; Hematologic Neoplasms; Humans; Multienzyme Complexes; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured | 2003 |
Targeting proteasome inhibition in hematologic malignancies.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Hematologic Neoplasms; Humans; Multienzyme Complexes; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines | 2003 |
Update on the proteasome inhibitor bortezomib in hematologic malignancies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Death; Clinical Trials as Topic; Cysteine Endopeptidases; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Models, Biological; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
Proteasome inhibition in hematologic malignancies.
Topics: Asthenia; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Diarrhea; Hematologic Neoplasms; Humans; Multienzyme Complexes; Nausea; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Survival Analysis; Treatment Outcome | 2004 |
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin | 2005 |
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Models, Molecular; Multiple Myeloma; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured | 2005 |
Proteasome inhibitors as therapeutics.
Topics: Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2005 |
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Pyrazines; Treatment Outcome | 2005 |
Proteasome inhibition: a new approach for the treatment of malignancies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Gastrointestinal Diseases; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Humans; Multiple Myeloma; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Primates; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Rodentia | 2005 |
Targeting the proteasome as a therapeutic strategy against haematological malignancies.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Hematologic Neoplasms; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2006 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Europe; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Multicenter Studies as Topic; Multiple Myeloma; National Institutes of Health (U.S.); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Procarbazine; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; United States; Vinblastine; Vincristine | 2006 |
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Lymphoma; Multiple Myeloma; Neoplasms; Protease Inhibitors; Pyrazines; Treatment Outcome | 2006 |
The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Hematologic Neoplasms; Humans; Pyrazines; Quinolones | 2007 |
The potential of proteasome inhibitors in cancer therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Drug Screening Assays, Antitumor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Proteins; Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Salvage Therapy; Ubiquitin; Ubiquitination | 2008 |
Proteasome inhibition in cancer: development of PS-341.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Cysteine Endopeptidases; Drug Screening Assays, Antitumor; Hematologic Neoplasms; Humans; Multienzyme Complexes; Multiple Myeloma; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Structure-Activity Relationship | 2001 |
Development of the proteasome inhibitor PS-341.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Mice; Mice, Nude; Multicenter Studies as Topic; Protease Inhibitors; Pyrazines; Rats | 2002 |
8 trial(s) available for pyrazines and Hematologic Neoplasms
| Article | Year |
|---|---|
Treatment of chronic graft-versus-host disease with bortezomib.
Topics: Animals; Boronic Acids; Bortezomib; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines; Scleroderma, Systemic; Skin; Transplantation, Homologous; Treatment Outcome; Tumor Cells, Cultured | 2014 |
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Living Donors; Male; Methotrexate; Pyrazines; Stem Cell Transplantation; Survival Rate; Tacrolimus; Time Factors; Transplantation Conditioning; Transplantation, Homologous | 2009 |
Carfilzomib: a novel second-generation proteasome inhibitor.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Hematologic Neoplasms; Humans; Multiple Myeloma; Neutropenia; Oligopeptides; Proteasome Inhibitors; Protein Binding; Pyrazines; Thrombocytopenia | 2011 |
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
Topics: Adult; Aged; Antilymphocyte Serum; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Lymphocyte Depletion; Male; Methotrexate; Middle Aged; Pyrazines; Tacrolimus; Unrelated Donors | 2012 |
In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies.
Topics: Adult; Cord Blood Stem Cell Transplantation; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Fetal Blood; Hematologic Neoplasms; Humans; Male; Middle Aged; Pilot Projects; Pyrazines; Sitagliptin Phosphate; Transplantation Conditioning; Triazoles; Young Adult | 2013 |
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Drug Administration Schedule; Enzyme Inhibitors; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Multienzyme Complexes; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome; United States | 2002 |
New developments with bortezomib in treating multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Division; Doxorubicin; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Liposomes; Lymphoma, Non-Hodgkin; Multiple Myeloma; Peripheral Nervous System Diseases; Polyethylene Glycols; Pyrazines; Renal Insufficiency; Treatment Outcome | 2004 |
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Female; Hematologic Neoplasms; Humans; Liposomes; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2005 |
24 other study(ies) available for pyrazines and Hematologic Neoplasms
| Article | Year |
|---|---|
Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies
Topics: Adult; Amides; Azithromycin; Child; COVID-19; Hematologic Neoplasms; Humans; Hydroxychloroquine; Pyrazines; SARS-CoV-2; Turkey | 2022 |
Hematological Malignancy Patients, COVID-19, and Favipiravir
Topics: Amides; COVID-19; Hematologic Neoplasms; Humans; Pyrazines; SARS-CoV-2 | 2021 |
Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Citrus paradisi; Citrus sinensis; Comorbidity; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inducers; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Food-Drug Interactions; Fruit and Vegetable Juices; Hematologic Neoplasms; Humans; Lymphoproliferative Disorders; Piperidines; Polypharmacy; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction | 2020 |
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Mutant Proteins; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins c-kit; Pyrazines; Pyrazoles; Pyrroles; Sorafenib; Staurosporine; Triazines | 2019 |
Children are not large mice.
Topics: Adolescent; Animals; Antineoplastic Agents; Apoptosis; Bone Resorption; Boronic Acids; Bortezomib; Child; Child, Preschool; Chondrocytes; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Infant; Mice; Pyrazines | 2013 |
Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation.
Topics: Area Under Curve; Cord Blood Stem Cell Transplantation; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Population; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Histocompatibility Antigens Class I; HLA Antigens; Humans; Interferon-gamma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Up-Regulation | 2014 |
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.
Topics: Active Transport, Cell Nucleus; Adaptor Proteins, Signal Transducing; Analysis of Variance; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; DNA Damage; DNA Primers; Doxorubicin; Fluorescent Antibody Technique; Genetic Vectors; Genomic Instability; Hematologic Neoplasms; Humans; Immunohistochemistry; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Phosphoproteins; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-abl; Pyrazines; Real-Time Polymerase Chain Reaction; Transcription Factors; YAP-Signaling Proteins | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Glycine; Hematologic Neoplasms; Humans; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin | 2015 |
A C-terminal fragment of Cyclin E, generated by caspase-mediated cleavage, is degraded in the absence of a recognizable phosphodegron.
Topics: Antigens, Nuclear; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Cullin Proteins; Cyclin E; DNA-Binding Proteins; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Half-Life; Hematologic Neoplasms; Humans; Isoenzymes; Ku Autoantigen; Neoplasm Proteins; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-mdm2; Pyrazines; S-Phase Kinase-Associated Proteins; Ubiquitin-Protein Ligases; Ubiquitination | 2008 |
In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytotoxins; Drug Interactions; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured | 2009 |
Targeted therapy and hematological malignancy.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Benzamides; Biomedical Research; Boronic Acids; Bortezomib; CD52 Antigen; Drug Design; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Glycoproteins; Hematologic Neoplasms; Humans; Imatinib Mesylate; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pulse Therapy, Drug; Pyrazines; Pyrimidines; Rituximab; Survival Rate | 2009 |
Rapid fatal pulmonary complications in a Chinese patient after bortezomib treatment for ALK-negative anaplastic large-cell lymphoma.
Topics: Aged; Asian People; Boronic Acids; Bortezomib; Enzyme Inhibitors; Fatal Outcome; Hematologic Neoplasms; Humans; Lung; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Male; Pyrazines | 2010 |
Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Jurkat Cells; Lymphocytes; Myeloid Cell Leukemia Sequence 1 Protein; Protein Binding; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2011 |
Microscale functional cytomics for studying hematologic cancers.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cells, Cultured; Cellular Microenvironment; Coculture Techniques; Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Immunohistochemistry; Multiple Myeloma; NF-kappa B; Pyrazines; STAT3 Transcription Factor; Stromal Cells; Tumor Necrosis Factor-alpha | 2012 |
Graft-versus-host disease: have we solved the problem?
Topics: Antigens, CD34; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Pyrazines; Siblings; T-Lymphocyte Subsets | 2012 |
Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Dimerization; Drug Synergism; Hematologic Neoplasms; Humans; K562 Cells; Lymphoma; NF-kappa B; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Receptors, Glucocorticoid; RNA Interference; RNA, Small Interfering; Transcription Factor AP-1; Transcriptional Activation; Triazoles; Tumor Cells, Cultured | 2013 |
Clinical trials referral resource. Current clinical trials of bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Neoplasms; Humans; National Institutes of Health (U.S.); Neoplasms; Patient Selection; Protease Inhibitors; Pyrazines; United States | 2003 |
Hematologic malignancies: from clinical science to clinical practice - 2nd European Congress.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematologic Neoplasms; Humans; Ki-1 Antigen; Molecular Structure; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Catalytic Domain; Cell Line, Tumor; Drug Screening Assays, Antitumor; Hematologic Neoplasms; Humans; Leukemia; Mice; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2007 |
American Society of Hematology--48th Annual Meeting and Exposition. Updates on hematological therapies. 9-12 December 2006 Orlando, FL, USA.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Hematologic Neoplasms; Hematology; Humans; Indoles; Janus Kinase 2; Lactams, Macrocyclic; Myeloproliferative Disorders; Phosphorylcholine; Pyrazines | 2007 |
Correspondence re: C.V. Rao, et al., Inhibition of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced lymphoma formation by oltipraz. Cancer Res., 56: 3395-3398, 1996.
Topics: Aflatoxin B1; Animals; Anticarcinogenic Agents; Hematologic Neoplasms; Imidazoles; Lymphoma; Male; Pyrazines; Rats; Rats, Inbred F344; Thiones; Thiophenes | 1997 |
Clinical trials referral resource. Current clinical trials for the proteasome inhibitor PS-341.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Hematologic Neoplasms; Humans; Neoplasms; Protease Inhibitors; Pyrazines | 2000 |